Clay Siegall- Witness of Cancer Patient Developing New Cures

Dr. Clay Siegall is the CEO of Seattle Genetics. He founded the company himself in 1998. Seattle Genetics helps cancer patients. Dr. Siegall graduated from The University of Maryland with a Bachelor’s degree in zoology. He holds a PhD in genetics from George Washington University. As an undergraduate at UMD, cancer treatment became one of his interests. Recognition was a motivation for Siegall for becoming a business owner.

Seattle Genetics makes its profits from drug sales, production partnerships, and process and technology licensing. The company became lucrative approximately 10 years after the initial public offering. Siegall was doubtful on his startup’s performance during its working capital depletion. He handled that situation through preparation and perseverance. The first customer at Seattle Genetics was brought in skilled sellers and quality products. Siegall believes that good work habits, such as passion and concentration, make him successful.

Siegall thinks that systemic chemotherapies will be a thing of the past. These therapies will be replaced with targeted therapies. In 2011, the FDA approved one of Seattle Genetic’s therapies. The name of this therapy is ADCETRIS (brentuximab vedotin). It was the first ADC (Antibody-Drug Conjugate) product developed by the company.

Dr. Siegall serves on the Board of Directors of Alder Biopharmaceuticals. He is on the Board of Governors of Fred Hutchinson Cancer Research Center. Siegall is a board member at Mirna Therapeutics. As of January 30, 2014, Dr. Clay Siegall was appointed to the Board of Directors of Ultragenix. Siegall is the current Chairman of the Board of Directors at Seattle Genetics. He has authored over 70 publications. Furthermore, Siegall has 15 patents.

From 1988 to 1991, Clay was a team member at National Institutes of Health. He held the same role at Genentech, PDL Biopharma, Curagen Corporation, MedImmune, and the National Cancer Institute. Prior to starting up Seattle Genetics, he was employed by Bristol-Myers Squib from 1991 to 1997.

In 2012, Siegall was nominated as Entrepreneur of the Year by the Pacific Northwest program at Ernst & Young. As of 2013, he was the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences.